IPMN, accordingly, showed intermediate expression of BCL9L, but instead demonstrated a high expression of the cyclin D1 inhibitor INPP5D, possibly contributing to the better prognosis of this neoplasia compared to PDAC. This evidence concerns the gene BCL9L and pancreatic intraductal papillary-mucinous neoplasm.